{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:41:06Z","timestamp":1767829266848,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jchromb.2020.122474","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T14:04:04Z","timestamp":1610460244000},"page":"122474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration, using LC\u2013MS\/MS"],"prefix":"10.1016","volume":"1164","author":[{"given":"Catherine E.","family":"DelGuidice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omnia A.","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"William R.","family":"Mylott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Halquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122474_b0005","doi-asserted-by":"crossref","DOI":"10.1007\/s00216-017-0607-0","article-title":"Development of an LC-MS\/MS method with protein G purification strategy for quantifying bevacizumab in human plasma","author":"Chiu","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.jchromb.2020.122474_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dmpk.2015.11.004","article-title":"Fully validated LCMS bioanalysis of bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"31","author":"Iwamoto","year":"2016","journal-title":"DrugMetab Pharmacokinet."},{"key":"10.1016\/j.jchromb.2020.122474_b0015","unstructured":"Genentech, Avastin: Highlights of Prescribing Information, 2004. Retrieved from: https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf."},{"key":"10.1016\/j.jchromb.2020.122474_b0020","unstructured":"Genentech, Lucentis: Highlights of Prescribing Information, 2006. Retrieved from: https:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf."},{"issue":"11","key":"10.1016\/j.jchromb.2020.122474_b0025","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1021\/acs.analchem.9b00971","article-title":"Direct mass spectrometry analysis of protein complexes and intact proteins up to >70 kDa from tissue","volume":"91","author":"Griffiths","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.122474_b0030","first-page":"1","article-title":"LC\/MS analysis of the monoclonal antibody rituximab using the Q exactive benchtop orbitrap mass spectrometer","volume":"591","author":"Samonig","year":"2016","journal-title":"Thermo Sci. Bull. Appl."},{"key":"10.1016\/j.jchromb.2020.122474_b0035","unstructured":"Z. Tingting, D. Zhenyu, X. Qun, J. Rohrer, High-Resolution Separation of a Fusion Protein, 2016, pp. 6\u20138. Retrieved from https:\/\/assets.thermofisher.com\/TFS-Assets\/CMD\/Application-Notes\/AB-171-LC-High-Resolution-Fusion-Protein-AN71205-EN.pdf."},{"issue":"4","key":"10.1016\/j.jchromb.2020.122474_b0040","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1021\/acs.analchem.6b04997","article-title":"Generic hybrid ligand binding assay liquid chromatography high-resolution mass spectrometry-based workflow for multiplexed human immunoglobulin G1 quantification at the intact protein level: application to preclinical pharmacokinetic studies","volume":"89","author":"Lanshoeft","year":"2017","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jchromb.2020.122474_b0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jasms.2008.11.011","article-title":"Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody","volume":"20","author":"Liu","year":"2009","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"5","key":"10.1016\/j.jchromb.2020.122474_b0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/mabs.25423","article-title":"Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques","volume":"5","author":"Resemann","year":"2013","journal-title":"MAbs"},{"issue":"20","key":"10.1016\/j.jchromb.2020.122474_b0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.4155\/bio-2016-0180","article-title":"A whole-molecule immu\u00acnocapture LC-MS approach for the in vivo quantitation of biotherapeutics","volume":"8","author":"Kellie","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2020.122474_b0060","series-title":"Application of Liquid Chromatogra\u00acphy-High Resolution Mass Spectrometry in the Quantification of Intact Proteins in Biological Fluids. Protein Analysis Using Mass Spectrometry: Accelerating Protein Biotherapeutics from Lab to Patient","first-page":"129","author":"Zhang","year":"2017"},{"issue":"28","key":"10.1016\/j.jchromb.2020.122474_b0065","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1007\/s00216-017-0607-0","article-title":"Development of an LC-MS\/MS method with protein G purification strategy for quantifying Bevacizumab in human plasma","volume":"409","author":"Chiu","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2020.122474_b0070","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.talanta.2017.01.023","article-title":"Analysis of therapeutic monoclonal antibody glycoforms by mass spectrometry for pharmacokinetics study","volume":"165","author":"Cong","year":"2017","journal-title":"Talanta"},{"issue":"16","key":"10.1016\/j.jchromb.2020.122474_b0075","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4155\/bio-2016-0096","article-title":"A workflow for absolute quantitation of large ther\u00acapeutic proteins in biological samples at intact level using LC-HRMS","volume":"8","author":"Jian","year":"2016","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.jchromb.2020.122474_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14789450.2018.1404907","article-title":"The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins","volume":"15","author":"O\u2019Flaherty","year":"2018","journal-title":"Expert Rev. Proteomic"},{"issue":"23","key":"10.1016\/j.jchromb.2020.122474_b0085","doi-asserted-by":"crossref","first-page":"11670","DOI":"10.1021\/acs.analchem.6b03252","article-title":"In vivo biotransformation of the fusion protein tetranectin-apolipoprotein A1 analyzed by ligand-binding mass spectrometry com\u00acbined with quantitation by ELISA","volume":"88","author":"Zell","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.122474_b0090","unstructured":"S. Bechler, K. Cook, K. Flook, Monoclonal Antibody Analysis on a Re\u00acversed-Phase C4 Polymer Monolith Column, 2016. Retrieved from: https:\/\/assets.ther\u00acmofisher.com\/TFS-Assets\/CMD\/Application-Notes\/AN-21163-LC-ProSwift-C4-RP-5H-Monoclonal-Antibody-AN21163-EN.pdf."},{"issue":"23","key":"10.1016\/j.jchromb.2020.122474_b0095","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.4155\/bio-2017-0179","article-title":"Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis","volume":"9","author":"Kellie","year":"2017","journal-title":"Bioanalysis"},{"issue":"23","key":"10.1016\/j.jchromb.2020.122474_b0100","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1021\/acs.analchem.6b03410","article-title":"Custom-designed affinity capture LC-MS F(ab\u2032)2 assay for biotransformation assessment of site-specific antibody drug conjugates","volume":"88","author":"Su","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.122474_b0105","unstructured":"ProteinSimple R&D Systems, Human Vascular Endothelial Growth Factor A Specification Sheet, 2015. Retrieved from: https:\/\/www.proteinsimple.com\/documents\/VEGF-A_Specification_Sheet_D10-1015-001.pdf."},{"issue":"4","key":"10.1016\/j.jchromb.2020.122474_b0110","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular edema","volume":"97","author":"Zehetner","year":"2013","journal-title":"Brit. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.jchromb.2020.122474_b0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00417-014-2717-0","article-title":"Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration","volume":"252","author":"Yoshida","year":"2014","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"issue":"12","key":"10.1016\/j.jchromb.2020.122474_bib116","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Brit. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.jchromb.2020.122474_bib117","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"10.1016\/j.jchromb.2020.122474_bib118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2018.05.007","article-title":"Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum","volume":"461","author":"Lowe","year":"2018","journal-title":"J. Immunol. Methods"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:03:08Z","timestamp":1761606188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023220313507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"alternative-id":["S1570023220313507"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122474","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration, using LC\u2013MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122474"}}